Drug
Tavaborole clinical trials
Also written AN2690.
- studies test it
- 11
- open now
- 0
- in phase 3
- 2
- first study started
- 2005
How studies write it
Studies that test it under each name
Brand
Development codes
Studies by the year they started
11 studies that test it; most in 2006 (4)
| Year | Studies |
|---|---|
| 2005 | 1 |
| 2006 | 4 |
| 2007 | 3 |
| 2010 | 1 |
| 2011 | 1 |
| 2015 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 1
- Phase 2
- 7
- Phase 3
- 2
- Phase 4
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 11 · Other 0
Studies
Open first, then newest update. How each study uses tavaborole is read from its arms, and is right about nine times in ten.
Testing it · 11
- Cumulative Irritation TestCompletedPhase 1PfizerNCT00680095Written as AN2690
- Efficacy and Safety of AN2690 Topical Solution to Treat Onychomycosis of the ToenailCompletedPhase 3PfizerNCT01302119Written as AN2690 Topical Solution, 5%
- Efficacy and Safety Evaluation of AN2690 Topical Solution to Treat Onychomycosis of the ToenailCompletedPhase 3PfizerNCT01270971Written as AN2690 Topical Solution, 5%
- Absorption and Systemic Study of AN2690 in Patients With Moderate to Severe Onychomycosis (ADME I)CompletedPhase 2PfizerNCT00680160Written as AN2690
- Study of Different Doses of a Novel Treatment for OnychomycosisCompletedPhase 2PfizerNCT00679965Written as AN2690, 2.5%
- Safety and Efficacy Study of Subjects With Onychomycosis of the Great ToenailCompletedPhase 2PfizerNCT01278394Written as AN2690 Solution, 5.0%
- Safety and Efficacy Study of Subjects With Onychomycosis of the Great ToenailCompletedPhase 2PfizerNCT00679523Written as AN2690 Solution, 5.0%
- An Evaluation of the Safety and Pharmacokinetics of Tavaborole Topical Solution for the Treatment of Fungal Disease of the Toenail in Children and AdolescentsCompletedPhase 4PfizerNCT03405818Written as Tavaborole 5% Topical Solution
- Absorption and Systemic Study of AN2690 in Patients With Moderate to Severe Onychomycosis (ADME II)CompletedPhase 2PfizerNCT00679601Written as AN2690
- Safety and Efficacy Evaluation of Topically Applied AN2690 Solutions for Subjects With OnychomycosisCompletedPhase 2PfizerNCT00680134Written as AN2690
- Study of Different Doses of a Novel Treatment for OnychomycosisCompletedPhase 2PfizerNCT00679770Written as AN2690, 2.5%
Codes
What other systems call tavaborole · ClinicalTrials.gg INT004962
- MeSH (NLM) C512998tavaboroleConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) K124A4EUQ3TAVABOROLEConfirmed FDA, NLM, Wikidata
- RxNorm 1543173Confirmed FDA, Wikidata
- Wikidata Q21011226tavaboroleConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C81725TavaboroleOne source FDA
- DrugBank DB09041One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C512998 | tavaborole | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | K124A4EUQ3 | TAVABOROLE | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1543173 | — | Confirmed FDA, Wikidata |
| Wikidata | Q21011226 | tavaborole | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C81725 | Tavaborole | One source FDA |
| DrugBank | DB09041 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.